European Union - English - EMA (European Medicines Agency)

teva b.v. - reslizumab - asthma - other systemic drugs for obstructive airway diseases, - cinqaero is indicated as add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - reslizumab - solution for infusion - 10mg/1ml

Ireland - English - HPRA (Health Products Regulatory Authority)

animalcare limited - isoflurane - inhalation vapour liquid - 1000 mg/g - reslizumab - avian, canine, equine - food, feline, ferret, gerbils, guinea pigs, hamsters, reptile - neurological preparations

European Union - English - EMA (European Medicines Agency)

astrazeneca ab - roflumilast - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - libertek is indicated for maintenance treatment of severe chronic obstructive pulmonary disease (copd) (fev1 post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add-on to bronchodilator treatment.

Canada - English - Health Canada

teva canada limited - reslizumab - solution - 10mg - reslizumab 10mg - interleukin antagonists

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - reslizumab - solution for infusion - 10mg/1ml

Israel - English - Ministry of Health

teva israel ltd - reslizumab - concentrate for solution for infusion - reslizumab 10 mg / 1 ml - reslizumab - cinqair is indicated for the add-on maintenance treatment of patients with severe asthma aged 18 years and older with an eosinophilic phenotype [see clinical studies (14)].limitation of use:• cinqair is not indicated for treatment of other eosinophilic conditions.• cinqair is not indicated for the relief of acute bronchospasm or status asthmaticus